FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Supplemental Application (Teva Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for lisdexamfetamine dimesylate from Teva Pharmaceuticals under an ANDA, approving changes to the generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Binge Eating Disorder

Drugs mentioned

• LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

SUPPL AP for LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)